See also:


MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN). In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families.

Contact information:


Acquiring an MPN: Is There a Familial Predisposition?

Dedicated MPN researcher Dr. Angela Fleischman discusses advances in understanding the disease course of an MPN and identifying the inherited risk for families.


Genetic Mutations in MPNs: Learning About Prognosis and Progression

MPN experts Dr. Angela Fleischman and Dr. John Crispino discuss the latest MPN prognostic tools and how mutational status can be used to assess the risk of disease progression.


Expert Outlook: New Avenues in MPN Treatment

Are there new JAK inhibitors in development for MPN patients? What treatment options are there if JAK inhibitors stop working? Learn more from MPN experts Dr. Angela Fleischman and Dr. John Crispino.


Preventing Progression in MPNs: Researcher Perspectives From ASH 2017

MPN experts Dr. Angela Fleischman and Dr. John Crispino share their insights on clinical data released at ASH 2017 related to disease-modifying agents that may impact progression. Watch now to find out the latest.


The Latest MPN News: What the Experts Learned at ASH 2017

As part of our ASH 2017 coverage, Dr. John Crispino and Dr. Angela Fleischman, joined Patient Power to share what they learned at this year’s annual meeting. Watch to learn the latest about MPNs.


The Goal of Myelofibrosis (MF) Treatment

MPN expert, Dr. John Mascarenhas from Mount Sinai School of Medicine, gives a concise, yet comprehensive, overview of myelofibrosis (MF) treatments.


The Goal of Essential Thrombocythemia (ET) Treatment

MPN expert, Dr. John Mascarenhas from Mount Sinai School of Medicine, explains the goal of various common treatments for essential thrombocythemia (ET).


Treating Polycythemia Vera (PV) With Phlebotomy

Dr. Mark Heaney from Columbia University Medical Center discusses phlebotomy, the cornerstone of polycythemia vera (PV) treatment, as well as cytoreductive therapies.


Expert Update: The Status of JAK Inhibitors in Development

What is the developmental status of JAK inhibitors? Drs. Mark Heaney and John Mascarenhas update us on this extremely important question.


Join Our Community Register for Events Read Our Latest Blog

Page last updated on November 20, 2017